IPP Bureau
GelMEDIX partners with Catalent to advance vision-restoring cell therapies
By IPP Bureau - March 14, 2026
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Veristat expands global trial & regulatory services as Chinese drugmakers push overseas
By IPP Bureau - March 14, 2026
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Biogen unveils promising new data for Salanersen in kids with SMA
By IPP Bureau - March 14, 2026
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Zydus receives USFDA approval for cevimeline hydrochloride capsules
By IPP Bureau - March 14, 2026
Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.
Caplin Steriles gets USFDA approval for potassium phosphates injection
By IPP Bureau - March 14, 2026
Single-use gloves misused across India, raising health risks
By IPP Bureau - March 14, 2026
One task, one interaction, one pair, experts advocate
Aster DM bags overwhelming shareholder backing for merger with Quality Care
By IPP Bureau - March 14, 2026
The endorsement follows overwhelming support for the share swap preceding the merger,
Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing
By IPP Bureau - March 14, 2026
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Wanbury bags key Brazil nod, eyes market expansion
By IPP Bureau - March 14, 2026
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO
By IPP Bureau - March 14, 2026
The conflict is also triggering a widening public health emergency
Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore
By IPP Bureau - March 14, 2026
Remidex manufactures micronutrient premixes and nutraceuticals,
APL Healthcare’s Unit-IV classified as VAI by the USFDA
By IPP Bureau - March 14, 2026
This inspection is now closed
AI boom, screen overload quietly stealing India’s sleep, new survey warns
By IPP Bureau - March 14, 2026
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
By IPP Bureau - March 14, 2026
The protections extend through at least 2035, with the potential for further extensions
